The GLP-1 program is available exclusively to employees whose employer offers Vitable Primary Care as part of their benefits package. Clinical eligibility is determined by a Vitable provider and follows FDA guidelines: employees must have a BMI over 30, or a BMI over 27 with at least one weight-related health condition (e.g., hypertension, Type 2 diabetes, high cholesterol).
A safer path to GLP-1s and weight loss
Vitable’s GLP-1 Program delivers a safer path to medications like Wegovy® and Zepbound®, fully backed by our trusted Primary Care. Each member receives consistent clinical oversight, behavioral support, and personalized care before, during, and after treatment—for safer, more sustainable weight loss.
Features
A clinically sound, cost-effective
GLP-1 solution for your workforce
Vitable’s GLP-1 Program challenges the prescription-first model with a safer, longitudinal approach. It’s a high-touch, provider-led model that combines evidence-based care with flexible pricing , so you can offer meaningful diabetes and weight management support to the employees who need it most.
Weight loss backed by primary care
GLP-1s are breakthrough medications that help with diabetes management and weight loss by reducing appetite, regulating insulin, and improving metabolism. With the rise in popularity, many GLP-1 medications are being prescribed without proper guidance and oversight. Vitable’s GLP-1 Program is fully backed by our trusted Primary Care model — so you’re supported every step of the way.
- 01
Personalized clinical evaluation
Starts with a one-on-one visit to determine if GLP-1 medication is the right fit for your health and goals.
- 02
Prescriptions from trusted providers
If eligible, a Vitable provider will prescribe Wegovy® or Zepbound® — brand-name medications sourced directly from the manufacturers.
- 03
Ongoing monitoring & support
We don’t set it and forget it. Vitable offers regular check-ins to adjust dosage, manage side effects, and support long-term success.
- 04
Lower costs through employer subsidies
There may be potential employer subsidies for qualifying members that could significantly reduce out-of-pocket costs.
Wegovy by Novo Nordisk
Wegovy (semaglutide) is a once-weekly injectable GLP-1 receptor agonist approved by the FDA specifically for chronic weight management in adults with obesity or those who are overweight with weight-related health conditions. At Vitable, we source Wegovy directly from Novo Nordisk through their NovoCare platform, ensuring access to the safest, most reliable version of the medication. Unlike compounded alternatives — which face ongoing legal and safety concerns — branded Wegovy has undergone rigorous clinical trials and is manufactured under strict regulatory standards. By prescribing Wegovy through a Vitable provider, patients benefit from personalized care, medical oversight, and continuity that supports long-term success.
Zepbound by Eli Lilly
Zepbound (tirzepatide) is an advanced GLP-1/GIP receptor agonist developed by Eli Lilly and approved for weight management in adults with obesity or those who are overweight with related health risks. Through LillyDirect, Vitable provides patients with direct access to Zepbound at one of the lowest available prices — without relying on compounded or non-standard versions. As the compounded market shifts under legal scrutiny and potential safety risks, Vitable remains committed to clinical integrity by sourcing Zepbound directly from the manufacturer. Our provider-led program integrates Zepbound into a comprehensive care model that includes pre-screening, routine follow-ups, and a health-first approach to weight management.
Vitable GLP-1 Program vs. Others
Other
GLP-1 Programs
GLP-1 Programs
FDA-Compliant, No Compounded Drugs
High-Touch, Provider-Led Care
Behavioral Change & Lifestyle Support
Employer Subsidies for High-BMI Members
Mental Health Support
Primary Care Coverage with $0 Copays or Deductibles
Holistic, Long-Term Health Management
Employer Dashboard for Easy Benefit Management
Frequently Asked Questions
Who qualifies for Vitable’s GLP-1 program?
What GLP-1 medications are included — and why does that matter?
Vitable only prescribes FDA-approved, branded medications: Wegovy® (semaglutide) and Zepbound® (tirzepatide). These are sourced directly from the manufacturers (Novo Nordisk and Eli Lilly), ensuring the highest standard of safety and compliance. We do not use compounded versions, which face legal and clinical scrutiny across the industry.
How is Vitable’s program different from other GLP-1 offerings?
Unlike many pop-up clinics that focus on volume and shortcuts, Vitable’s program is fully integrated into our primary care model. Employees receive care from licensed providers, with clinical screenings, same-provider follow-ups, lifestyle support, and long-term monitoring — not just a prescription.
What does the program cost — for employers and employees?
Vitable’s GLP-1 program is available through Vitable Primary Care, offered to employers for as little as $1 per employee per day.
Employees pay $499/month for medication; however, high-BMI members may qualify for subsidies that reduce the cost to as low as $99/month. If you're interested in learning more about subsidy eligibility, please speak with a Vitable team member.
How do employees access the program?
Once enrolled in a Vitable plan, employees can schedule a virtual visit with a provider through the platform. If eligible, the provider sends the prescription directly to the manufacturer’s pharmacy (NovoCare or LillyDirect). Eligible employees will receive direct-to-home delivery, and ongoing care continues through their dedicated Vitable provider — with no gaps in support.
_GLP-1%20%20PR%20Blog.png)
_Apaly%20PR%20Blog.png)